FLAGSHIP PIONEERING INNOVATIONS V, INC.

Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.

Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.

Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.

Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.

Methods and compositions for introducing, modifying, or expressing foreign genetic material within plant cells to confer new traits, produce novel compounds, or enhance existing characteristics.

Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.

Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.

Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.

Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.

Development and application of living organisms (e.g., bacteria, fungi, viruses) or their natural derivatives (e.g., peptides, plant extracts) as agents to suppress or eliminate agricultural pests, weeds, or plant diseases.

Engineering or breeding plants to exhibit enhanced resistance or tolerance to pathogens (fungi, bacteria, viruses) or pests, often involving the identification and introduction of specific resistance genes or genomic regions.

Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.

Methods and compositions that stimulate a plant's natural defense mechanisms or improve its physiological resilience against pathogens, pests, or environmental stressors, rather than directly eliminating the threat.

Development and characterization of novel plant varieties or cultivars, including field crops, vegetables, fruits, and ornamental plants, focusing on improved agronomic performance, aesthetic qualities, or specific product characteristics.

Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.

Utilization of specific DNA sequences (markers) to identify, select, or characterize plant varieties or traits, enabling more efficient breeding, quality control, and intellectual property protection.

Technologies focused on enhancing the stability, efficacy, spread, or targeted application of biocidal active ingredients through specialized carriers, adjuvants, encapsulation, or physical forms (e.g., gels, spray-dried particles).